| 11/18/2026 7:01 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/17/2026 3:50 PM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/17/2026 3:34 PM | Enlivex Therapeutics (1596812) Filer | Form 424B5 | |
| 11/17/2026 3:40 PM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/16/2026 7:00 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/02/2026 7:02 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/28/2026 7:01 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/27/2026 7:01 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/22/2026 4:17 PM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/19/2026 7:18 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/29/2026 4:10 PM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Get the Latest News and Ratings for ENLV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 09/22/2026 7:02 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/14/2026 7:52 PM | Enlivex Therapeutics (1596812) Filer | Form 424B3 | |
| 08/13/2026 11:15 PM | Enlivex Therapeutics (1596812) Filer | Form EFFECT | |
| 08/13/2026 3:04 PM | Enlivex Therapeutics (1596812) Subject Lind Partners LLC (1812439) Filed by | Form SCHEDULE 13G | |
| 08/06/2026 3:43 PM | Enlivex Therapeutics (1596812) Filer | Form F-3 Registration statement for securities of certain foreign private issuers | |
| 07/30/2026 7:02 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/20/2026 7:01 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/13/2026 7:00 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/07/2026 7:01 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/24/2026 7:01 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/22/2026 7:50 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/28/2026 7:05 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/27/2026 7:05 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/18/2026 7:02 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/15/2026 3:15 PM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/01/2026 3:16 PM | Enlivex Therapeutics (1596812) Filer | Form 424B3 | |
| 04/21/2026 3:15 PM | Enlivex Therapeutics (1596812) Filer | Form F-3 Registration statement for securities of certain foreign private issuers | |
| 04/21/2026 7:32 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/08/2026 7:33 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/26/2026 7:32 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/25/2026 7:40 AM | Enlivex Therapeutics (1596812) Filer | Form 20-F Registration statement / Annual report / Transition report | |
| 03/25/2026 7:31 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/24/2026 7:34 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/23/2026 7:02 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/20/2026 3:05 PM | Enlivex Therapeutics (1596812) Filer | Form 424B3 | |
| 03/18/2026 6:13 AM | Enlivex Therapeutics (1596812) Issuer Hart Gili (1971738) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 6:14 AM | Enlivex Therapeutics (1596812) Issuer Shlosberger Shachar (2075724) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 6:15 AM | Enlivex Therapeutics (1596812) Issuer Hershkovitz Oren (2075956) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 6:01 AM | Enlivex Therapeutics (1596812) Issuer Galamidi Einat (2076463) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 6:03 AM | Enlivex Therapeutics (1596812) Issuer Havron Avraham (1971756) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
Your Social Security check is scheduled for a 22% cut (Ad) The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year.
The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%.
A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold. Download the free Debt Death Spiral report now |
| 03/18/2026 6:04 AM | Enlivex Therapeutics (1596812) Issuer Pomerantz Roger (1614936) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 6:08 AM | Enlivex Therapeutics (1596812) Issuer NOVIK SHAI A (1401412) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/13/2026 3:17 PM | Enlivex Therapeutics (1596812) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 02/23/2026 7:00 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/10/2026 7:02 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/05/2026 6:50 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/26/2026 7:01 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/23/2026 7:03 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/07/2026 7:02 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/04/2026 11:15 PM | Enlivex Therapeutics (1596812) Filer | Form EFFECT | |
| 12/23/2025 3:37 PM | Enlivex Therapeutics (1596812) Filer | Form F-3 Registration statement for securities of certain foreign private issuers | |
| 12/18/2025 3:30 PM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/04/2025 7:02 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/26/2025 7:03 AM | Enlivex Therapeutics (1596812) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |